ACAD - ACADIA Pharmaceuticals Inc.
| Previous Close | 19.66 |
| Open | 19.76 |
| Bid | 19.46 x 1000 |
| Ask | 19.85 x 800 |
| Day's Range | 19.20 - 20.00 |
| 52 Week Range | 15.74 - 41.20 |
| Volume | 1,551,857 |
| Avg. Volume | 2,591,450 |
| Market Cap | 2.482B |
| Beta | 3.91 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.36 |
| Earnings Date | May 7, 2018 - May 11, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 50.14 |
- ACCESSWIRE•2 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Acadia Pharmaceuticals Inc. - ACAD
NEW YORK, NY / ACCESSWIRE / April 20, 2018 / Pomerantz LLP is investigating claims on behalf of investors of Acadia Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). ...
- CNBC•3 days ago
Cramer's lightning round: International Paper is a 'very good buy' at these prices
It's that time again! "Mad Money" host Jim Cramer rang the lightning round bell, which means he gave his take on callers' favorite stocks at rapid speed. A lot of people feel world commerce is going to slow down, a lot of different crosscurrents because of tariffs.
- ACCESSWIRE•8 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Acadia Pharmaceuticals Inc. - ACAD
NEW YORK, NY / ACCESSWIRE / April 14, 2018 / Pomerantz LLP is investigating claims on behalf of investors of Acadia Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). ...
Markit•9 days agoSee what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding ACAD totaled $633 million.
- Simply Wall St.•11 days ago
ACADIA Pharmaceuticals Inc (NASDAQ:ACAD): Does The Earnings Decline Make It An Underperformer?
Understanding ACADIA Pharmaceuticals Inc’s (NASDAQ:ACAD) performance as a company requires examining more than earnings from one point in time. Today I will take you through a basic sense check toRead More...
- PR Newswire•12 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Acadia Pharmaceuticals Inc. - ACAD
NEW YORK , April 10, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Acadia Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). ...
- Motley Fool•12 days ago
Don't Try to Catch This Falling Knife
Acadia's stock dropped hard yesterday on a report from CNN, but that doesn't mean it's time to buy.
- ACCESSWIRE•12 days ago
Today’s Research Reports on Stocks to Watch: ACADIA Pharmaceuticals and Menlo Therapeutics
NEW YORK, NY / ACCESSWIRE / April 10, 2018 / Negative news about Acadia's Nuplazid drug being a suspect in many adverse event related deaths had Wall Street on edge yesterday, sending shares of the biotech ...
Markit•12 days agoSee what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc NASDAQ/NGS:ACAD
- InvestorPlace•13 days ago
Why ACADIA Pharmaceuticals Inc. Stock Is Plunging Today
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) stock was falling hard today on an article about its drug Nuplazid. Nuplazid is a drug that was given approval by the U.S. Food and Drug Administration (FDA) and started being sold to customers in June 2016. The drug was given fast-track approval by the FDA, despite concerns that it may not actually help those suffering from Parkinson’s disease.
- PR Newswire•13 days ago
ACADIA INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In ACADIA Pharmaceuticals Inc. To Contact The Firm
NEW YORK , April 9, 2018 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against ACADIA Pharmaceuticals Inc. ("ACADIA" or the "Company") ...
- Benzinga•13 days ago
Acadia Shares Hurting On Reports Of Nuplazid Deaths
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) faded 24 percent Monday after CNN exposed the deaths of more than 700 Nuplazid patients since the drug’s June 2016 launch. The U.S. Food and Drug Administration ...
- Motley Fool•13 days ago
Why Acadia Pharmaceuticals Is Crashing Today
Traders flee after a troublesome news report emerged related to the company's only drug, Nuplazid. Here's what investors need to know.
Markit•17 days agoSee what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc NASDAQ/NGS:ACAD
- Motley Fool•19 days ago
Better Buy: Acadia Pharmaceuticals vs. Eli Lilly
These two pharma companies are in very different stages of their life cycle, but which is more deserving of capital today?
- ACCESSWIRE•26 days ago
Today’s Research Reports on Trending Tickers: ACADIA Pharmaceuticals and Immunomedics
NEW YORK, NY / ACCESSWIRE / March 27, 2018 / U.S markets rallied Monday, after posting their worst weekly loss in two years last week, on easing tensions between the U.S. and China. The Dow Jones Industrial ...
- Investopedia•last month
Biotech Acadia's Stock May Double On Sales Spike
Acadia Pharmaceuticals stock could soar on back of robust sales projections for its Parkinson's disease drug Nuplazid.
- Motley Fool•last month
Is Acadia Pharmaceuticals a Buy?
Wall Street thinks Acadia Pharmaceuticals is a screaming buy, but there are several reasons to think otherwise.
- Business Wire•last month
ACADIA Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference on March 27, 2018
ACADIA Pharmaceuticals Inc. , a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the 17th Annual Needham Healthcare Conference on Tuesday, March 27, 2018, at 11:30 a.m.
- Motley Fool•last month
Is Acadia Pharmaceuticals Stock Now a Strong Buy?
Acadia's stock has fallen on hard times. Is it now a bargain?
Markit•last monthSee what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc NASDAQ/NGS:ACAD
- ACCESSWIRE•2 months ago
Wired News – Clearside BioMedical Reported Positive Top-line Results from Phase-3 Trial Assessing CLS-TA in Macular Edema Associated with Non-infectious Uveitis
Stock Monitor: ACADIA Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 07, 2018 / Active-Investors.com has just released a free research report on Clearside BioMedical, Inc. (NASDAQ: CLSD ...
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of ACAD earnings conference call or presentation 27-Feb-18 10:00pm GMT
Q4 2017 ACADIA Pharmaceuticals Inc Earnings Call
- Business Wire•2 months ago
ACADIA Pharmaceuticals to Present at the Cowen and Company 38th Annual Health Care Conference on March 13, 2018
ACADIA Pharmaceuticals Inc. , a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the Cowen and Company 38th Annual Health Care Conference on Tuesday, March 13, 2018, at 8:40 a.m.
- CNBC Videos•3 days ago
Cramer's lightning round: International Paper is a 'very ...
Jim Cramer zooms through his take on callers' favorite stocks, including a play on global commerce.
